Q4 2024 Earnings Call Transcript February 19, 2025 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
It wasn't perhaps the most glamorous of unveilings. Indeed, one would imagine grander plans are already being hatched for the ...
What you should knowEagles fans swarmed the streets to take in the Super Bowl victory parade, camping out all day as the team ...
Juneau Empire on MSN5d
Alaska state employees rally for more pay and benefits on same day mass federal firings occurAs thousands of federal workers were being fired on Valentine’s Day by the Trump administration, a group of about 70 state ...
Your twenties aren't a race, so why rush it? While reaching milestones as a twenty-something is fantastic, the reality is ...
UroGen Pharma (URGN) announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and ...
David Koch, the economic director at Compare the Market and former Sunrise host, said an upcoming rate cut had “been a long time coming” and would give much needed “breathing room in the ...
Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
Despite February delivery dips, Boeing is well-positioned to sustainably increase delivery volumes, supporting a buy rating ...
The Trump administration, reportedly, is seeking to renegotiate awards under the U.S. CHIPS and Science Act awards.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback